{
  "id": "topic4",
  "title": "Topic 4: Neurological, Neuromuscular, Autism Spectrum & Developmental Disorders Study Guide",
  "description": "[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.",
  "difficulty": "Advanced",
  "tags": [
    "neurological",
    "developmental",
    "intellectual-disability",
    "autism"
  ],
  "estimatedTime": 19,
  "importance": 1,
  "sections": [
    {
      "id": "quick-navigation",
      "title": "Quick Navigation",
      "content": "**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Organ Systems](topic3-organ-systems-a.md)** | **[‚û°Ô∏è Next: Metabolic Disorders](topic5-metabolic-disorders.md)**\n\n### üìã Table of Contents\n- [üéØ Learning Objectives](#-learning-objectives)\n- [üìö Section 1: Trinucleotide Repeat Disorders](#-section-1-trinucleotide-repeat-disorders)\n  - [Huntington Disease (HD)](#11-huntington-disease-hd)\n  - [Fragile X Syndrome](#12-fragile-x-syndrome)\n  - [Myotonic Dystrophy Type 1 (DM1)](#13-myotonic-dystrophy-type-1-dm1)\n- [üìö Section 2: X-Linked Neuromuscular Disorders](#-section-2-x-linked-neuromuscular-disorders)\n  - [Duchenne Muscular Dystrophy (DMD)](#21-duchenne-muscular-dystrophy-dmd)\n  - [Becker Muscular Dystrophy (BMD)](#22-becker-muscular-dystrophy-bmd)\n  - [Spinal Muscular Atrophy (SMA)](#23-spinal-muscular-atrophy-sma)\n- [üìö Section 3: Autism Spectrum & Neurodevelopmental Disorders](#-section-3-autism-spectrum--neurodevelopmental-disorders)\n  - [Autism Spectrum Disorder (ASD)](#31-autism-spectrum-disorder-asd---genetic-evaluation)\n  - [Rett Syndrome](#32-rett-syndrome)\n  - [Intellectual Disability Evaluation](#33-intellectual-disability-evaluation-algorithm)\n- [üìö Section 4: Neural Tube Defects & Congenital Anomalies](#-section-4-neural-tube-defects--congenital-anomalies)\n  - [Neural Tube Defects (NTDs)](#41-neural-tube-defects-ntds)\n  - [CHARGE Syndrome](#42-charge-syndrome)\n  - [RASopathies Overview](#43-rasopathies-overview)\n- [üß† Clinical Testing Strategies](#-clinical-testing-strategies)\n- [üí° High-Yield Study Tips](#-high-yield-study-tips)\n- [üìù Memory Aids & Mnemonics](#-memory-aids--mnemonics)\n- [üéØ Board-Style Practice Questions](#-board-style-practice-questions)\n- [‚úÖ Topic 4 Completion Checklist](#-topic-4-completion-checklist)\n\n### üîç Quick Disorder Lookup\n| Disorder | Gene(s) | Key Features | Inheritance | Anticipation |\n|----------|---------|--------------|-------------|-------------|\n| **Huntington Disease** | HTT | Chorea, cognitive decline | AD | Paternal |\n| **Fragile X** | FMR1 | ID, autism, macro-orchidism | X-linked | Maternal |\n| **Myotonic Dystrophy** | DMPK | Myotonia, cataracts, cardiac | AD | Maternal |\n| **Duchenne MD** | DMD | Progressive weakness, CK >10K | X-linked | - |\n| **SMA** | SMN1 | Proximal weakness, preserved cognition | AR | - |\n| **Rett Syndrome** | MECP2 | Regression, hand stereotypies | X-linked | - |\n| **CHARGE** | CHD7 | Coloboma, heart defects, choanal atresia | AD | - |\n| **Noonan** | PTPN11, SOS1 | Short stature, cardiac, bleeding | AD | - |\n\n### üèÜ Board Exam Domain Coverage\n- **Primary Domain:** Clinical Genetics (40-50%)\n- **Secondary Domains:** General Genetics/Genomics (15-25%), Psychosocial/Counseling (10-20%)\n- **Difficulty Level:** Intermediate to Advanced\n- **Estimated Study Time:** 12-15 hours\n- **Last Updated:** July 2025\n\n---",
      "importance": 1
    },
    {
      "id": "learning-objectives",
      "title": "Learning Objectives",
      "content": "By completing this topic, you will be able to:\n\n1. **Master trinucleotide repeat disorders** including anticipation patterns, repeat thresholds, and testing methodologies\n2. **Differentiate X-linked disorders** (Duchenne/Becker MD, Fragile X, Rett) and explain inheritance risks\n3. **Calculate recurrence risks** for neural tube defects and apply folate prevention strategies\n4. **Interpret molecular testing** for neuromuscular disorders including deletion/duplication analysis\n5. **Recognize clinical features** of major neurodevelopmental syndromes for differential diagnosis\n6. **Apply genetic testing algorithms** for autism spectrum disorders and intellectual disability\n7. **Counsel families** about carrier screening for SMA and expanded carrier panels\n8. **Explain anticipation** in Huntington disease and myotonic dystrophy with specific examples\n9. **Identify RASopathies** and distinguish between Noonan spectrum disorders\n10. **Integrate prenatal screening** findings with diagnostic testing for congenital anomalies\n\n---",
      "importance": 1
    },
    {
      "id": "section-1-trinucleotide-repeat-disorders",
      "title": "\udcda Section 1: Trinucleotide Repeat Disorders",
      "content": "<details>\n<summary><strong>üìú Overview</strong> (Click to expand)</summary>\n\nTrinucleotide repeat disorders involve unstable expansions of DNA repeats that tend to increase in size when transmitted to offspring, leading to anticipation (earlier onset and increased severity in successive generations).\n\n</details>\n\n### 1.1 Huntington Disease (HD)\n\n#### üîë Key Features (Top 3)\n1. **Classic Triad:** Chorea + Progressive motor disability + Cognitive decline\n2. **Paternal anticipation** - juvenile onset with paternal transmission\n3. **Pre-symptomatic testing** - requires extensive counseling\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Classic Triad:** Chorea + Progressive motor disability + Cognitive decline\n- **Additional Features:** Behavioral changes (irritability, depression), dysarthria, dysphagia\n- **Age of Onset:** Typically 30-50 years (juvenile onset <20 years with paternal transmission)\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** HTT (chromosome 4p16.3)\n- **Repeat:** CAG in exon 1\n- **Inheritance:** Autosomal dominant\n- **Repeat Thresholds:**\n  - Normal: <26 CAG repeats\n  - Intermediate: 27-35 repeats (not affected, but unstable)\n  - Reduced penetrance: 36-39 repeats\n  - Full penetrance: ‚â•40 repeats\n  - Juvenile onset: >60 repeats (usually paternal transmission)\n\n</details>\n\n<details>\n<summary><strong>üß™ Testing Considerations</strong> (Click to expand)</summary>\n\n- Pre-symptomatic testing requires extensive counseling\n- Consider psychological evaluation before testing\n- Insurance and employment discrimination concerns\n- Testing minors is generally not recommended\n\n</details>\n\n#### üíé Board Pearl\n> Paternal transmission more likely to result in expansion and juvenile onset due to instability during spermatogenesis\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Fragile X Syndrome](#12-fragile-x-syndrome)**\n\n### 1.2 Fragile X Syndrome\n\n#### üîë Key Features (Top 3)\n1. **Most common inherited cause of ID** - especially in males\n2. **Maternal anticipation** - expansion risk increases with repeat size\n3. **Premutation carrier risks** - POI in females, FXTAS in males\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Males:** Intellectual disability, autism spectrum behaviors, macro-orchidism (post-pubertal)\n- **Females:** Variable presentation (mild ID to normal intelligence)\n- **Facial Features:** Long face, prominent ears, prominent jaw\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** FMR1 (Xq27.3)\n- **Repeat:** CGG in 5' UTR\n- **Inheritance:** X-linked dominant with reduced penetrance\n- **Repeat Thresholds:**\n  - Normal: 5-44 CGG repeats\n  - Intermediate: 45-54 repeats\n  - Premutation: 55-200 repeats\n  - Full mutation: >200 repeats (hypermethylation)\n\n</details>\n\n<details>\n<summary><strong>‚ö†Ô∏è Premutation Carrier Risks</strong> (Click to expand)</summary>\n\n- **Females:** Primary ovarian insufficiency (POI) ~20%\n- **Males >50 years:** Fragile X-associated tremor/ataxia syndrome (FXTAS) ~40%\n- **Expansion Risk:** Depends on maternal repeat size\n  - 55-59 repeats: 3.7% risk\n  - 70-79 repeats: 31.1% risk\n  - 90-99 repeats: 80.1% risk\n  - >100 repeats: ~100% risk\n\n</details>\n\n<details>\n<summary><strong>üß™ Testing Strategy</strong> (Click to expand)</summary>\n\n- PCR with Southern blot for methylation status\n- Prenatal testing: Amniocentesis preferred over CVS\n- Carrier screening recommended for:\n  - Family history of FX or unexplained ID\n  - Women with POI <40 years\n  - Adults with late-onset ataxia/tremor\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Myotonic Dystrophy](#13-myotonic-dystrophy-type-1-dm1)**\n\n### 1.3 Myotonic Dystrophy Type 1 (DM1)\n\n#### üîë Key Features (Top 3)\n1. **Myotonia** - delayed muscle relaxation after contraction\n2. **Maternal anticipation** - congenital form with maternal transmission\n3. **Multi-system involvement** - cardiac, endocrine, ophthalmologic\n\n<details>\n<summary><strong>üè• Clinical Features by Type</strong> (Click to expand)</summary>\n\n- **Mild:** Cataracts, mild myotonia, diabetes\n- **Classic:** Myotonia, distal muscle weakness, cataracts, cardiac conduction defects\n- **Congenital:** Severe hypotonia, respiratory insufficiency, club foot, intellectual disability\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** DMPK (19q13.32)\n- **Repeat:** CTG in 3' UTR\n- **Inheritance:** Autosomal dominant\n- **Repeat Thresholds:**\n  - Normal: 5-34 CTG repeats\n  - Premutation: 35-49 repeats\n  - Mild DM1: 50-150 repeats\n  - Classic DM1: 100-1000 repeats\n  - Congenital: >1000 repeats (almost always maternal transmission)\n\n</details>\n\n<details>\n<summary><strong>üõ°Ô∏è Clinical Management</strong> (Click to expand)</summary>\n\n- Annual cardiac evaluation (conduction defects)\n- Cataract screening\n- Glucose monitoring\n- Anesthesia precautions (malignant hyperthermia-like reaction)\n\n</details>\n\n#### üìù Mnemonic for DM1: \"**MATCH**\"\n- **M**yotonia\n- **A**rrhythmias\n- **T**esticular atrophy/Cataracts\n- **C**ognitive impairment\n- **H**ypotonia (congenital)\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: X-Linked Neuromuscular Disorders](#-section-2-x-linked-neuromuscular-disorders)**\n\n---",
      "importance": 1
    },
    {
      "id": "section-2-xlinked-neuromuscular-disorders",
      "title": "\udcda Section 2: X-Linked Neuromuscular Disorders",
      "content": "### 2.1 Duchenne Muscular Dystrophy (DMD)\n\n#### üîë Key Features (Top 3)\n1. **Progressive proximal weakness** - wheelchair by age 13\n2. **Reading frame rule** - out-of-frame mutations = severe DMD\n3. **High CK levels** - >10,000 U/L diagnostic marker\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Progressive Pattern:** Proximal > distal weakness\n- **Milestones:** Wheelchair by age 13, death by late teens/early 20s\n- **Gower Sign:** Using hands to \"walk up\" legs when rising\n- **Calf Pseudohypertrophy:** Fatty infiltration of muscles\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** DMD (Xp21.2) - largest known human gene\n- **Mutations:** \n  - 60% deletions\n  - 20% duplications\n  - 20% point mutations\n- **De novo rate:** ~1/3 of cases\n- **Reading Frame Rule:**\n  - Out-of-frame mutations ‚Üí DMD (no dystrophin)\n  - In-frame mutations ‚Üí Becker MD (partial dystrophin)\n\n</details>\n\n<details>\n<summary><strong>üß™ Testing Algorithm</strong> (Click to expand)</summary>\n\n1. CK levels (>10,000 U/L in DMD)\n2. Deletion/duplication analysis (MLPA)\n3. If negative ‚Üí sequencing\n4. Muscle biopsy rarely needed\n\n</details>\n\n<details>\n<summary><strong>üß† Carrier Testing</strong> (Click to expand)</summary>\n\n- 2/3 of mothers are carriers\n- CK levels unreliable for carrier detection\n- Molecular testing required\n- Germline mosaicism risk: 7-10%\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Becker MD](#22-becker-muscular-dystrophy-bmd)**\n\n### 2.2 Becker Muscular Dystrophy (BMD)\n\n#### üîë Key Differences from DMD\n- Later onset (>16 years)\n- Ambulatory beyond age 16\n- Milder progression\n- In-frame mutations preserve partial dystrophin\n\n#### üíé Board Pearl\n> Exception to reading frame rule: Deletions of exons 3-7 can cause BMD despite being out-of-frame\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Spinal Muscular Atrophy](#23-spinal-muscular-atrophy-sma)**\n\n### 2.3 Spinal Muscular Atrophy (SMA)\n\n#### üîë Key Features (Top 3)\n1. **Anterior horn cell degeneration** - motor neuron disease\n2. **SMN2 copy number modifier** - determines severity\n3. **Universal carrier screening** - recommended for all couples\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Pathology:** Anterior horn cell degeneration\n- **Pattern:** Symmetric proximal > distal weakness\n- **Preserved:** Sensation and cognition\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** SMN1 (5q13)\n- **Modifier:** SMN2 copy number\n- **Inheritance:** Autosomal recessive\n- **Carrier Frequency:**\n  - Ashkenazi Jewish: 1/41 (90% detection)\n  - Asian: 1/53 (92.6% detection)\n  - African American: 1/66 (71.1% detection)\n  - Hispanic: 1/117 (90.6% detection)\n  - Caucasian: 1/35 (94.9% detection)\n\n</details>\n\n<details>\n<summary><strong>üìä SMA Types by SMN2 Copy Number</strong> (Click to expand)</summary>\n\n- **Type I (Werdnig-Hoffmann):** 1-2 copies, onset <6 months, never sit\n- **Type II:** 2-3 copies, onset 6-18 months, sit but never walk\n- **Type III (Kugelberg-Welander):** 3-4 copies, onset >18 months, walk initially\n- **Type IV:** 4+ copies, adult onset, mild symptoms\n\n</details>\n\n**Testing Considerations:**\n- 95% have homozygous SMN1 deletion\n- 5% compound heterozygous (deletion + point mutation)\n- 2% have one de novo mutation\n- Carrier screening recommended universally\n\n---",
      "importance": 1
    },
    {
      "id": "section-3-autism-spectrum-neurodevelopmental-disorders",
      "title": "\udcda Section 3: Autism Spectrum & Neurodevelopmental Disorders",
      "content": "### 3.1 Autism Spectrum Disorder (ASD) - Genetic Evaluation\n\n**Prevalence:** 1 in 68\n\n**Genetic Testing Yield:**\n- Chromosomal microarray (CMA): 10-15%\n- Fragile X testing: 2-5% (higher in males with ID)\n- Single gene testing: Variable based on phenotype\n\n**High-Yield Syndromic Causes:**\n- **Fragile X:** Most common inherited cause (males)\n- **Rett Syndrome:** Consider in females with regression\n- **MECP2 Duplication:** Males with ID, spasticity, seizures\n- **PTEN Mutation:** Macrocephaly + ASD\n- **Tuberous Sclerosis:** Skin findings + seizures\n- **Angelman Syndrome:** Happy demeanor, seizures, absent speech\n\n### 3.2 Rett Syndrome\n\n**Key Features:**\n- **Classic Presentation:** Normal development ‚Üí regression (6-18 months)\n- **Hallmark:** Loss of purposeful hand use ‚Üí stereotypic hand movements\n- **Additional:** Microcephaly, seizures, scoliosis, breathing abnormalities\n\n**Genetics:**\n- **Gene:** MECP2 (Xq28)\n- **Inheritance:** X-linked dominant, 99% de novo\n- **Male Lethality:** Most affected individuals are female\n- **Exceptions:** Males with Klinefelter (XXY) or somatic mosaicism\n\n**Diagnostic Criteria Mnemonic:** \"**HANDS**\"\n- **H**and stereotypies\n- **A**praxia/Ataxia\n- **N**ormal early development\n- **D**evelopmental regression\n- **S**peech loss\n\n### 3.3 Intellectual Disability Evaluation Algorithm\n\n**First Tier Testing:**\n1. Chromosomal microarray (15-20% yield)\n2. Fragile X testing\n3. Consider metabolic screening if indicated\n\n**Second Tier (if negative):**\n1. Whole exome sequencing (25-30% additional yield)\n2. Specific gene panels based on phenotype\n3. X-linked ID panel for males\n\n---",
      "importance": 1
    },
    {
      "id": "section-4-neural-tube-defects-congenital-anomalies",
      "title": "\udcda Section 4: Neural Tube Defects & Congenital Anomalies",
      "content": "### 4.1 Neural Tube Defects (NTDs)\n\n**Types & Timing:**\n- **Anencephaly:** Failure of rostral closure (day 24-26)\n- **Spina Bifida:** Failure of caudal closure (day 26-28)\n- **Encephalocele:** Skull defect with brain tissue herniation\n\n**Risk Factors:**\n- Previous NTD: 2-3% recurrence\n- Maternal diabetes: 2-3x increased risk\n- Valproic acid exposure: 1-2% risk\n- Folate deficiency\n- Obesity (BMI >30)\n- Hyperthermia in early pregnancy\n\n**Prevention & Counseling:**\n- **General Population:** 400 Œºg folic acid daily\n- **Previous NTD:** 4 mg folic acid daily (start 3 months preconception)\n- **High-Risk Medications:** 4 mg folic acid daily\n\n**Screening:**\n- AFP >2.5 MoM suggests open NTD\n- Ultrasound: Banana sign, lemon sign for spina bifida\n- Amniocentesis: Elevated AFP + acetylcholinesterase\n\n### 4.2 CHARGE Syndrome\n\n**Diagnostic Criteria - Major Features:**\n- **C**oloboma (iris/retina)\n- **H**eart defects (conotruncal)\n- **A**tresia of choanae\n- **R**etardation of growth/development\n- **G**enital hypoplasia\n- **E**ar anomalies/deafness\n\n**Genetics:**\n- **Gene:** CHD7 (8q12.2)\n- **Inheritance:** Autosomal dominant, mostly de novo\n- **Testing Yield:** 65-70% with sequencing\n\n**Clinical Diagnosis:**\n- 4 major features OR\n- 3 major + 3 minor features\n\n### 4.3 RASopathies Overview\n\n**Common Features:**\n- Short stature\n- Cardiac defects\n- Facial dysmorphism\n- Developmental delays\n- Increased tumor risk (some)\n\n### Noonan Syndrome\n\n**Key Features:**\n- **Cardiac:** Pulmonary valve stenosis (50%), HCM (20%)\n- **Face:** Hypertelorism, down-slanting eyes, low-set ears\n- **Other:** Webbed neck, pectus deformity, cryptorchidism\n- **Bleeding:** Factor XI deficiency, platelet dysfunction\n\n**Genetics:**\n- **PTPN11:** 50% (also causes LEOPARD syndrome)\n- **SOS1:** 10-20%\n- **RAF1:** 3-17% (higher HCM risk)\n- **Other:** KRAS, NRAS, BRAF, MAP2K1\n\n**Management:**\n- Growth hormone effective\n- Cardiac surveillance\n- Developmental support\n- Bleeding precautions pre-surgery\n\n**Noonan Differential Mnemonic:** \"**FRONT**\"\n- **F**acial features overlap\n- **R**ASopathy spectrum\n- **O**ther: Turner syndrome (females)\n- **N**eurodevelopmental delays\n- **T**umor risk (in some)\n\n---",
      "importance": 1
    },
    {
      "id": "clinical-testing-strategies",
      "title": "Clinical Testing Strategies",
      "content": "### Approach to Hypotonia\n1. **Central vs Peripheral:** Reflexes, CK levels\n2. **If Peripheral + ‚ÜëCK:** DMD/BMD testing\n3. **If Peripheral + Normal CK:** SMA testing\n4. **If Central:** CMA, consider Prader-Willi\n\n### Approach to Developmental Regression\n1. **With seizures:** Consider metabolic + mitochondrial\n2. **Female with hand stereotypies:** Rett syndrome\n3. **Male with spasticity:** MECP2 duplication\n4. **With autism features:** Comprehensive ASD panel\n\n### Trinucleotide Repeat Testing Indications\n- **Huntington:** Chorea + family history\n- **Fragile X:** ID + family history, POI, late ataxia\n- **Myotonic dystrophy:** Myotonia, cataracts, family history\n\n---",
      "importance": 1
    },
    {
      "id": "highyield-study-tips",
      "title": "\udca1 High-Yield Study Tips",
      "content": "### Anticipation Patterns\n- **Paternal:** Huntington (CAG), SCA (various)\n- **Maternal:** Myotonic dystrophy (CTG), Fragile X (CGG)\n- **Why:** Instability during gametogenesis differs by sex\n\n### X-Linked Recurrence Risks\n- **Carrier mother:** 50% sons affected, 50% daughters carriers\n- **Affected father:** 0% sons affected, 100% daughters carriers\n- **Remember:** Males can't pass X to sons\n\n### Repeat Expansion Mechanisms\n1. **Polyglutamine (CAG):** Protein aggregation (HD, SCAs)\n2. **RNA toxic gain:** Sequestration of proteins (DM1)\n3. **Loss of function:** Hypermethylation (Fragile X)\n\n### Testing Method Selection\n- **Deletions/Duplications:** MLPA, CMA\n- **Repeat expansions:** PCR + Southern blot\n- **Point mutations:** Sequencing\n- **Methylation:** MS-MLPA, bisulfite sequencing\n\n---",
      "importance": 1
    },
    {
      "id": "memory-aids-mnemonics",
      "title": "Memory Aids & Mnemonics",
      "content": "### \"CAGE\" for CAG Repeat Disorders\n- **C**horea (Huntington)\n- **A**taxia (SCAs)\n- **G**lutamine expansion\n- **E**arlier with paternal\n\n### \"DMD FROG\" for Duchenne Features\n- **F**rame shift mutations\n- **R**eading frame rule\n- **O**ut-of-frame = severe\n- **G**ower sign positive\n\n### \"MENTAL\" for ID Evaluation\n- **M**icroarray first\n- **E**xome if negative\n- **N**euroimaging if indicated\n- **T**argeted testing (Fragile X)\n- **A**ssess dysmorphology\n- **L**ook for regression\n\n### \"SPINE\" for SMA\n- **S**MN1 deletion\n- **P**roximal weakness\n- **I**ntelligence preserved\n- **N**umber of SMN2 copies matters\n- **E**arly treatment critical\n\n---",
      "importance": 1
    },
    {
      "id": "boardstyle-practice-questions",
      "title": "Board-Style Practice Questions",
      "content": "> **üìù Study Tip**: Try answering these questions before clicking for the answer. These mirror actual board exam question styles.\n\n### Question 1\nA 35-year-old man presents with progressive chorea and cognitive decline. His father died at age 45 with similar symptoms. Genetic testing reveals 42 CAG repeats in the HTT gene. His 25-year-old sister is considering predictive testing. What is the most important consideration?\n\nA) She has a 25% chance of inheriting the expansion\nB) Insurance discrimination is not a concern with GINA protection\nC) Psychological counseling should be provided before and after testing\nD) Testing should be delayed until she develops symptoms\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: C**\n*Explanation:* Pre-symptomatic testing for Huntington disease requires extensive genetic counseling and psychological support. While GINA provides some protection, it doesn't cover life or disability insurance. The sister has a 50% risk (not 25%). Testing asymptomatic individuals requires careful consideration of psychological readiness.\n</details>\n\n### Question 2\nA couple's first child has spinal muscular atrophy type I with 2 copies of SMN2. Both parents are confirmed carriers. What is the recurrence risk and likely prognosis for future affected children?\n\nA) 25% risk; variable severity depending on SMN2 copies\nB) 50% risk; all affected will have type I SMA\nC) 25% risk; severity correlates with SMN1 deletion size\nD) <1% risk due to de novo mutations\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A**\n*Explanation:* SMA is autosomal recessive with 25% recurrence risk. Severity correlates with SMN2 copy number (not SMN1 deletion size). While this child has type I, future affected children could have different SMN2 copy numbers and thus different severity.\n</details>\n\n### Question 3\nA 2-year-old girl presents with loss of purposeful hand movements and repetitive hand-wringing after normal early development. Which test is most appropriate?\n\nA) Chromosomal microarray\nB) MECP2 sequencing\nC) Metabolic screening\nD) SMN1 deletion analysis\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n*Explanation:* This presentation is classic for Rett syndrome. Regression after normal development with stereotypic hand movements strongly suggests MECP2 mutation. While CMA might be considered for ID evaluation, the specific phenotype directs testing.\n</details>\n\n### Question 4\nA woman with a family history of Fragile X syndrome is found to have 75 CGG repeats. What is her approximate risk of expansion to full mutation in offspring?\n\nA) 3.7%\nB) 31.1%\nC) 80.1%\nD) 100%\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n*Explanation:* Risk of expansion correlates with premutation size. For 70-79 repeats, the risk is approximately 31.1%. This risk increases with larger premutations, reaching near 100% for repeats >100.\n</details>\n\n### Question 5\nA newborn boy has severe hypotonia, respiratory distress, and club feet. His mother has mild grip myotonia. What is the most likely diagnosis?\n\nA) Congenital myotonic dystrophy\nB) Spinal muscular atrophy type 0\nC) Prader-Willi syndrome\nD) Duchenne muscular dystrophy\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A**\n*Explanation:* Congenital DM1 presents with severe hypotonia, respiratory issues, and club feet. Maternal transmission is almost universal for congenital form. Mother's mild myotonia suggests she has DM1 with smaller expansion.\n</details>\n\n### Question 6\nA couple's first pregnancy was affected with anencephaly. What folic acid supplementation is recommended for the next pregnancy?\n\nA) 400 Œºg daily starting at conception\nB) 400 Œºg daily starting 3 months pre-conception\nC) 4 mg daily starting at conception\nD) 4 mg daily starting 3 months pre-conception\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: D**\n*Explanation:* After a previous NTD, high-dose folic acid (4 mg) is recommended starting 3 months before conception and continuing through the first trimester. This reduces recurrence risk from 2-3% to approximately 1%.\n</details>\n\n### Question 7\nA 10-year-old boy with intellectual disability and autism has a head circumference >97th percentile. Which genetic test should be prioritized?\n\nA) Fragile X testing\nB) PTEN sequencing\nC) Chromosomal microarray\nD) MECP2 duplication testing\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n*Explanation:* Macrocephaly with ASD/ID strongly suggests PTEN mutation. While CMA is reasonable first-tier testing, the specific finding of macrocephaly directs testing toward PTEN-related disorders.\n</details>\n\n### Question 8\nA male infant has pulmonary valve stenosis, short stature, and cryptorchidism. His mother has similar facial features and short stature. What is the most likely diagnosis?\n\nA) Turner syndrome\nB) Noonan syndrome\nC) DiGeorge syndrome\nD) Williams syndrome\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n*Explanation:* Noonan syndrome features include pulmonary valve stenosis, short stature, cryptorchidism, and distinctive facial features. Autosomal dominant inheritance explains affected mother. Turner syndrome only affects females.\n</details>\n\n### Question 9\nIn Duchenne muscular dystrophy, which finding indicates carrier status in the mother?\n\nA) Elevated CK levels\nB) Calf pseudohypertrophy\nC) Molecular confirmation of heterozygous mutation\nD) Positive Gower sign\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: C**\n*Explanation:* Molecular testing is required for reliable carrier detection in DMD. CK levels are unreliable in carriers. Clinical findings are rare in carriers due to favorable X-inactivation.\n</details>\n\n### Question 10\nA 4-year-old boy has progressive proximal muscle weakness with preserved reflexes and normal intelligence. CK is 12,000. What is the best initial test?\n\nA) DMD deletion/duplication analysis\nB) SMN1 deletion analysis\nC) Muscle biopsy\nD) Nerve conduction studies\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A**\n*Explanation:* Very high CK with proximal weakness suggests muscular dystrophy. DMD deletion/duplication analysis detects 80% of mutations. This should be performed before invasive muscle biopsy. Normal reflexes argue against SMA.\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Completion Checklist](#-topic-4-completion-checklist)**\n\n---",
      "importance": 1
    }
  ],
  "objectives": [],
  "sectionCount": 13,
  "rawContent": "# Topic 4: Neurological, Neuromuscular, Autism Spectrum & Developmental Disorders Study Guide\n\n## üìñ Quick Navigation\n\n**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Organ Systems](topic3-organ-systems-a.md)** | **[‚û°Ô∏è Next: Metabolic Disorders](topic5-metabolic-disorders.md)**\n\n### üìã Table of Contents\n- [üéØ Learning Objectives](#-learning-objectives)\n- [üìö Section 1: Trinucleotide Repeat Disorders](#-section-1-trinucleotide-repeat-disorders)\n  - [Huntington Disease (HD)](#11-huntington-disease-hd)\n  - [Fragile X Syndrome](#12-fragile-x-syndrome)\n  - [Myotonic Dystrophy Type 1 (DM1)](#13-myotonic-dystrophy-type-1-dm1)\n- [üìö Section 2: X-Linked Neuromuscular Disorders](#-section-2-x-linked-neuromuscular-disorders)\n  - [Duchenne Muscular Dystrophy (DMD)](#21-duchenne-muscular-dystrophy-dmd)\n  - [Becker Muscular Dystrophy (BMD)](#22-becker-muscular-dystrophy-bmd)\n  - [Spinal Muscular Atrophy (SMA)](#23-spinal-muscular-atrophy-sma)\n- [üìö Section 3: Autism Spectrum & Neurodevelopmental Disorders](#-section-3-autism-spectrum--neurodevelopmental-disorders)\n  - [Autism Spectrum Disorder (ASD)](#31-autism-spectrum-disorder-asd---genetic-evaluation)\n  - [Rett Syndrome](#32-rett-syndrome)\n  - [Intellectual Disability Evaluation](#33-intellectual-disability-evaluation-algorithm)\n- [üìö Section 4: Neural Tube Defects & Congenital Anomalies](#-section-4-neural-tube-defects--congenital-anomalies)\n  - [Neural Tube Defects (NTDs)](#41-neural-tube-defects-ntds)\n  - [CHARGE Syndrome](#42-charge-syndrome)\n  - [RASopathies Overview](#43-rasopathies-overview)\n- [üß† Clinical Testing Strategies](#-clinical-testing-strategies)\n- [üí° High-Yield Study Tips](#-high-yield-study-tips)\n- [üìù Memory Aids & Mnemonics](#-memory-aids--mnemonics)\n- [üéØ Board-Style Practice Questions](#-board-style-practice-questions)\n- [‚úÖ Topic 4 Completion Checklist](#-topic-4-completion-checklist)\n\n### üîç Quick Disorder Lookup\n| Disorder | Gene(s) | Key Features | Inheritance | Anticipation |\n|----------|---------|--------------|-------------|-------------|\n| **Huntington Disease** | HTT | Chorea, cognitive decline | AD | Paternal |\n| **Fragile X** | FMR1 | ID, autism, macro-orchidism | X-linked | Maternal |\n| **Myotonic Dystrophy** | DMPK | Myotonia, cataracts, cardiac | AD | Maternal |\n| **Duchenne MD** | DMD | Progressive weakness, CK >10K | X-linked | - |\n| **SMA** | SMN1 | Proximal weakness, preserved cognition | AR | - |\n| **Rett Syndrome** | MECP2 | Regression, hand stereotypies | X-linked | - |\n| **CHARGE** | CHD7 | Coloboma, heart defects, choanal atresia | AD | - |\n| **Noonan** | PTPN11, SOS1 | Short stature, cardiac, bleeding | AD | - |\n\n### üèÜ Board Exam Domain Coverage\n- **Primary Domain:** Clinical Genetics (40-50%)\n- **Secondary Domains:** General Genetics/Genomics (15-25%), Psychosocial/Counseling (10-20%)\n- **Difficulty Level:** Intermediate to Advanced\n- **Estimated Study Time:** 12-15 hours\n- **Last Updated:** July 2025\n\n---\n\n## üéØ Learning Objectives\n\nBy completing this topic, you will be able to:\n\n1. **Master trinucleotide repeat disorders** including anticipation patterns, repeat thresholds, and testing methodologies\n2. **Differentiate X-linked disorders** (Duchenne/Becker MD, Fragile X, Rett) and explain inheritance risks\n3. **Calculate recurrence risks** for neural tube defects and apply folate prevention strategies\n4. **Interpret molecular testing** for neuromuscular disorders including deletion/duplication analysis\n5. **Recognize clinical features** of major neurodevelopmental syndromes for differential diagnosis\n6. **Apply genetic testing algorithms** for autism spectrum disorders and intellectual disability\n7. **Counsel families** about carrier screening for SMA and expanded carrier panels\n8. **Explain anticipation** in Huntington disease and myotonic dystrophy with specific examples\n9. **Identify RASopathies** and distinguish between Noonan spectrum disorders\n10. **Integrate prenatal screening** findings with diagnostic testing for congenital anomalies\n\n---\n\n## üìö Section 1: Trinucleotide Repeat Disorders\n\n<details>\n<summary><strong>üìú Overview</strong> (Click to expand)</summary>\n\nTrinucleotide repeat disorders involve unstable expansions of DNA repeats that tend to increase in size when transmitted to offspring, leading to anticipation (earlier onset and increased severity in successive generations).\n\n</details>\n\n### 1.1 Huntington Disease (HD)\n\n#### üîë Key Features (Top 3)\n1. **Classic Triad:** Chorea + Progressive motor disability + Cognitive decline\n2. **Paternal anticipation** - juvenile onset with paternal transmission\n3. **Pre-symptomatic testing** - requires extensive counseling\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Classic Triad:** Chorea + Progressive motor disability + Cognitive decline\n- **Additional Features:** Behavioral changes (irritability, depression), dysarthria, dysphagia\n- **Age of Onset:** Typically 30-50 years (juvenile onset <20 years with paternal transmission)\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** HTT (chromosome 4p16.3)\n- **Repeat:** CAG in exon 1\n- **Inheritance:** Autosomal dominant\n- **Repeat Thresholds:**\n  - Normal: <26 CAG repeats\n  - Intermediate: 27-35 repeats (not affected, but unstable)\n  - Reduced penetrance: 36-39 repeats\n  - Full penetrance: ‚â•40 repeats\n  - Juvenile onset: >60 repeats (usually paternal transmission)\n\n</details>\n\n<details>\n<summary><strong>üß™ Testing Considerations</strong> (Click to expand)</summary>\n\n- Pre-symptomatic testing requires extensive counseling\n- Consider psychological evaluation before testing\n- Insurance and employment discrimination concerns\n- Testing minors is generally not recommended\n\n</details>\n\n#### üíé Board Pearl\n> Paternal transmission more likely to result in expansion and juvenile onset due to instability during spermatogenesis\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Fragile X Syndrome](#12-fragile-x-syndrome)**\n\n### 1.2 Fragile X Syndrome\n\n#### üîë Key Features (Top 3)\n1. **Most common inherited cause of ID** - especially in males\n2. **Maternal anticipation** - expansion risk increases with repeat size\n3. **Premutation carrier risks** - POI in females, FXTAS in males\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Males:** Intellectual disability, autism spectrum behaviors, macro-orchidism (post-pubertal)\n- **Females:** Variable presentation (mild ID to normal intelligence)\n- **Facial Features:** Long face, prominent ears, prominent jaw\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** FMR1 (Xq27.3)\n- **Repeat:** CGG in 5' UTR\n- **Inheritance:** X-linked dominant with reduced penetrance\n- **Repeat Thresholds:**\n  - Normal: 5-44 CGG repeats\n  - Intermediate: 45-54 repeats\n  - Premutation: 55-200 repeats\n  - Full mutation: >200 repeats (hypermethylation)\n\n</details>\n\n<details>\n<summary><strong>‚ö†Ô∏è Premutation Carrier Risks</strong> (Click to expand)</summary>\n\n- **Females:** Primary ovarian insufficiency (POI) ~20%\n- **Males >50 years:** Fragile X-associated tremor/ataxia syndrome (FXTAS) ~40%\n- **Expansion Risk:** Depends on maternal repeat size\n  - 55-59 repeats: 3.7% risk\n  - 70-79 repeats: 31.1% risk\n  - 90-99 repeats: 80.1% risk\n  - >100 repeats: ~100% risk\n\n</details>\n\n<details>\n<summary><strong>üß™ Testing Strategy</strong> (Click to expand)</summary>\n\n- PCR with Southern blot for methylation status\n- Prenatal testing: Amniocentesis preferred over CVS\n- Carrier screening recommended for:\n  - Family history of FX or unexplained ID\n  - Women with POI <40 years\n  - Adults with late-onset ataxia/tremor\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Myotonic Dystrophy](#13-myotonic-dystrophy-type-1-dm1)**\n\n### 1.3 Myotonic Dystrophy Type 1 (DM1)\n\n#### üîë Key Features (Top 3)\n1. **Myotonia** - delayed muscle relaxation after contraction\n2. **Maternal anticipation** - congenital form with maternal transmission\n3. **Multi-system involvement** - cardiac, endocrine, ophthalmologic\n\n<details>\n<summary><strong>üè• Clinical Features by Type</strong> (Click to expand)</summary>\n\n- **Mild:** Cataracts, mild myotonia, diabetes\n- **Classic:** Myotonia, distal muscle weakness, cataracts, cardiac conduction defects\n- **Congenital:** Severe hypotonia, respiratory insufficiency, club foot, intellectual disability\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** DMPK (19q13.32)\n- **Repeat:** CTG in 3' UTR\n- **Inheritance:** Autosomal dominant\n- **Repeat Thresholds:**\n  - Normal: 5-34 CTG repeats\n  - Premutation: 35-49 repeats\n  - Mild DM1: 50-150 repeats\n  - Classic DM1: 100-1000 repeats\n  - Congenital: >1000 repeats (almost always maternal transmission)\n\n</details>\n\n<details>\n<summary><strong>üõ°Ô∏è Clinical Management</strong> (Click to expand)</summary>\n\n- Annual cardiac evaluation (conduction defects)\n- Cataract screening\n- Glucose monitoring\n- Anesthesia precautions (malignant hyperthermia-like reaction)\n\n</details>\n\n#### üìù Mnemonic for DM1: \"**MATCH**\"\n- **M**yotonia\n- **A**rrhythmias\n- **T**esticular atrophy/Cataracts\n- **C**ognitive impairment\n- **H**ypotonia (congenital)\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: X-Linked Neuromuscular Disorders](#-section-2-x-linked-neuromuscular-disorders)**\n\n---\n\n## üìö Section 2: X-Linked Neuromuscular Disorders\n\n### 2.1 Duchenne Muscular Dystrophy (DMD)\n\n#### üîë Key Features (Top 3)\n1. **Progressive proximal weakness** - wheelchair by age 13\n2. **Reading frame rule** - out-of-frame mutations = severe DMD\n3. **High CK levels** - >10,000 U/L diagnostic marker\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Progressive Pattern:** Proximal > distal weakness\n- **Milestones:** Wheelchair by age 13, death by late teens/early 20s\n- **Gower Sign:** Using hands to \"walk up\" legs when rising\n- **Calf Pseudohypertrophy:** Fatty infiltration of muscles\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** DMD (Xp21.2) - largest known human gene\n- **Mutations:** \n  - 60% deletions\n  - 20% duplications\n  - 20% point mutations\n- **De novo rate:** ~1/3 of cases\n- **Reading Frame Rule:**\n  - Out-of-frame mutations ‚Üí DMD (no dystrophin)\n  - In-frame mutations ‚Üí Becker MD (partial dystrophin)\n\n</details>\n\n<details>\n<summary><strong>üß™ Testing Algorithm</strong> (Click to expand)</summary>\n\n1. CK levels (>10,000 U/L in DMD)\n2. Deletion/duplication analysis (MLPA)\n3. If negative ‚Üí sequencing\n4. Muscle biopsy rarely needed\n\n</details>\n\n<details>\n<summary><strong>üß† Carrier Testing</strong> (Click to expand)</summary>\n\n- 2/3 of mothers are carriers\n- CK levels unreliable for carrier detection\n- Molecular testing required\n- Germline mosaicism risk: 7-10%\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Becker MD](#22-becker-muscular-dystrophy-bmd)**\n\n### 2.2 Becker Muscular Dystrophy (BMD)\n\n#### üîë Key Differences from DMD\n- Later onset (>16 years)\n- Ambulatory beyond age 16\n- Milder progression\n- In-frame mutations preserve partial dystrophin\n\n#### üíé Board Pearl\n> Exception to reading frame rule: Deletions of exons 3-7 can cause BMD despite being out-of-frame\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Spinal Muscular Atrophy](#23-spinal-muscular-atrophy-sma)**\n\n### 2.3 Spinal Muscular Atrophy (SMA)\n\n#### üîë Key Features (Top 3)\n1. **Anterior horn cell degeneration** - motor neuron disease\n2. **SMN2 copy number modifier** - determines severity\n3. **Universal carrier screening** - recommended for all couples\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n- **Pathology:** Anterior horn cell degeneration\n- **Pattern:** Symmetric proximal > distal weakness\n- **Preserved:** Sensation and cognition\n\n</details>\n\n<details>\n<summary><strong>üß¨ Genetics</strong> (Click to expand)</summary>\n\n- **Gene:** SMN1 (5q13)\n- **Modifier:** SMN2 copy number\n- **Inheritance:** Autosomal recessive\n- **Carrier Frequency:**\n  - Ashkenazi Jewish: 1/41 (90% detection)\n  - Asian: 1/53 (92.6% detection)\n  - African American: 1/66 (71.1% detection)\n  - Hispanic: 1/117 (90.6% detection)\n  - Caucasian: 1/35 (94.9% detection)\n\n</details>\n\n<details>\n<summary><strong>üìä SMA Types by SMN2 Copy Number</strong> (Click to expand)</summary>\n\n- **Type I (Werdnig-Hoffmann):** 1-2 copies, onset <6 months, never sit\n- **Type II:** 2-3 copies, onset 6-18 months, sit but never walk\n- **Type III (Kugelberg-Welander):** 3-4 copies, onset >18 months, walk initially\n- **Type IV:** 4+ copies, adult onset, mild symptoms\n\n</details>\n\n**Testing Considerations:**\n- 95% have homozygous SMN1 deletion\n- 5% compound heterozygous (deletion + point mutation)\n- 2% have one de novo mutation\n- Carrier screening recommended universally\n\n---\n\n## üìö Section 3: Autism Spectrum & Neurodevelopmental Disorders\n\n### 3.1 Autism Spectrum Disorder (ASD) - Genetic Evaluation\n\n**Prevalence:** 1 in 68\n\n**Genetic Testing Yield:**\n- Chromosomal microarray (CMA): 10-15%\n- Fragile X testing: 2-5% (higher in males with ID)\n- Single gene testing: Variable based on phenotype\n\n**High-Yield Syndromic Causes:**\n- **Fragile X:** Most common inherited cause (males)\n- **Rett Syndrome:** Consider in females with regression\n- **MECP2 Duplication:** Males with ID, spasticity, seizures\n- **PTEN Mutation:** Macrocephaly + ASD\n- **Tuberous Sclerosis:** Skin findings + seizures\n- **Angelman Syndrome:** Happy demeanor, seizures, absent speech\n\n### 3.2 Rett Syndrome\n\n**Key Features:**\n- **Classic Presentation:** Normal development ‚Üí regression (6-18 months)\n- **Hallmark:** Loss of purposeful hand use ‚Üí stereotypic hand movements\n- **Additional:** Microcephaly, seizures, scoliosis, breathing abnormalities\n\n**Genetics:**\n- **Gene:** MECP2 (Xq28)\n- **Inheritance:** X-linked dominant, 99% de novo\n- **Male Lethality:** Most affected individuals are female\n- **Exceptions:** Males with Klinefelter (XXY) or somatic mosaicism\n\n**Diagnostic Criteria Mnemonic:** \"**HANDS**\"\n- **H**and stereotypies\n- **A**praxia/Ataxia\n- **N**ormal early development\n- **D**evelopmental regression\n- **S**peech loss\n\n### 3.3 Intellectual Disability Evaluation Algorithm\n\n**First Tier Testing:**\n1. Chromosomal microarray (15-20% yield)\n2. Fragile X testing\n3. Consider metabolic screening if indicated\n\n**Second Tier (if negative):**\n1. Whole exome sequencing (25-30% additional yield)\n2. Specific gene panels based on phenotype\n3. X-linked ID panel for males\n\n---\n\n## üìö Section 4: Neural Tube Defects & Congenital Anomalies\n\n### 4.1 Neural Tube Defects (NTDs)\n\n**Types & Timing:**\n- **Anencephaly:** Failure of rostral closure (day 24-26)\n- **Spina Bifida:** Failure of caudal closure (day 26-28)\n- **Encephalocele:** Skull defect with brain tissue herniation\n\n**Risk Factors:**\n- Previous NTD: 2-3% recurrence\n- Maternal diabetes: 2-3x increased risk\n- Valproic acid exposure: 1-2% risk\n- Folate deficiency\n- Obesity (BMI >30)\n- Hyperthermia in early pregnancy\n\n**Prevention & Counseling:**\n- **General Population:** 400 Œºg folic acid daily\n- **Previous NTD:** 4 mg folic acid daily (start 3 months preconception)\n- **High-Risk Medications:** 4 mg folic acid daily\n\n**Screening:**\n- AFP >2.5 MoM suggests open NTD\n- Ultrasound: Banana sign, lemon sign for spina bifida\n- Amniocentesis: Elevated AFP + acetylcholinesterase\n\n### 4.2 CHARGE Syndrome\n\n**Diagnostic Criteria - Major Features:**\n- **C**oloboma (iris/retina)\n- **H**eart defects (conotruncal)\n- **A**tresia of choanae\n- **R**etardation of growth/development\n- **G**enital hypoplasia\n- **E**ar anomalies/deafness\n\n**Genetics:**\n- **Gene:** CHD7 (8q12.2)\n- **Inheritance:** Autosomal dominant, mostly de novo\n- **Testing Yield:** 65-70% with sequencing\n\n**Clinical Diagnosis:**\n- 4 major features OR\n- 3 major + 3 minor features\n\n### 4.3 RASopathies Overview\n\n**Common Features:**\n- Short stature\n- Cardiac defects\n- Facial dysmorphism\n- Developmental delays\n- Increased tumor risk (some)\n\n### Noonan Syndrome\n\n**Key Features:**\n- **Cardiac:** Pulmonary valve stenosis (50%), HCM (20%)\n- **Face:** Hypertelorism, down-slanting eyes, low-set ears\n- **Other:** Webbed neck, pectus deformity, cryptorchidism\n- **Bleeding:** Factor XI deficiency, platelet dysfunction\n\n**Genetics:**\n- **PTPN11:** 50% (also causes LEOPARD syndrome)\n- **SOS1:** 10-20%\n- **RAF1:** 3-17% (higher HCM risk)\n- **Other:** KRAS, NRAS, BRAF, MAP2K1\n\n**Management:**\n- Growth hormone effective\n- Cardiac surveillance\n- Developmental support\n- Bleeding precautions pre-surgery\n\n**Noonan Differential Mnemonic:** \"**FRONT**\"\n- **F**acial features overlap\n- **R**ASopathy spectrum\n- **O**ther: Turner syndrome (females)\n- **N**eurodevelopmental delays\n- **T**umor risk (in some)\n\n---\n\n## üß† Clinical Testing Strategies\n\n### Approach to Hypotonia\n1. **Central vs Peripheral:** Reflexes, CK levels\n2. **If Peripheral + ‚ÜëCK:** DMD/BMD testing\n3. **If Peripheral + Normal CK:** SMA testing\n4. **If Central:** CMA, consider Prader-Willi\n\n### Approach to Developmental Regression\n1. **With seizures:** Consider metabolic + mitochondrial\n2. **Female with hand stereotypies:** Rett syndrome\n3. **Male with spasticity:** MECP2 duplication\n4. **With autism features:** Comprehensive ASD panel\n\n### Trinucleotide Repeat Testing Indications\n- **Huntington:** Chorea + family history\n- **Fragile X:** ID + family history, POI, late ataxia\n- **Myotonic dystrophy:** Myotonia, cataracts, family history\n\n---\n\n## üí° High-Yield Study Tips\n\n### Anticipation Patterns\n- **Paternal:** Huntington (CAG), SCA (various)\n- **Maternal:** Myotonic dystrophy (CTG), Fragile X (CGG)\n- **Why:** Instability during gametogenesis differs by sex\n\n### X-Linked Recurrence Risks\n- **Carrier mother:** 50% sons affected, 50% daughters carriers\n- **Affected father:** 0% sons affected, 100% daughters carriers\n- **Remember:** Males can't pass X to sons\n\n### Repeat Expansion Mechanisms\n1. **Polyglutamine (CAG):** Protein aggregation (HD, SCAs)\n2. **RNA toxic gain:** Sequestration of proteins (DM1)\n3. **Loss of function:** Hypermethylation (Fragile X)\n\n### Testing Method Selection\n- **Deletions/Duplications:** MLPA, CMA\n- **Repeat expansions:** PCR + Southern blot\n- **Point mutations:** Sequencing\n- **Methylation:** MS-MLPA, bisulfite sequencing\n\n---\n\n## üìù Memory Aids & Mnemonics\n\n### \"CAGE\" for CAG Repeat Disorders\n- **C**horea (Huntington)\n- **A**taxia (SCAs)\n- **G**lutamine expansion\n- **E**arlier with paternal\n\n### \"DMD FROG\" for Duchenne Features\n- **F**rame shift mutations\n- **R**eading frame rule\n- **O**ut-of-frame = severe\n- **G**ower sign positive\n\n### \"MENTAL\" for ID Evaluation\n- **M**icroarray first\n- **E**xome if negative\n- **N**euroimaging if indicated\n- **T**argeted testing (Fragile X)\n- **A**ssess dysmorphology\n- **L**ook for regression\n\n### \"SPINE\" for SMA\n- **S**MN1 deletion\n- **P**roximal weakness\n- **I**ntelligence preserved\n- **N**umber of SMN2 copies matters\n- **E**arly treatment critical\n\n---\n\n## üéØ Board-Style Practice Questions\n\n> **üìù Study Tip**: Try answering these questions before clicking for the answer. These mirror actual board exam question styles.\n\n### Question 1\nA 35-year-old man presents with progressive chorea and cognitive decline. His father died at age 45 with similar symptoms. Genetic testing reveals 42 CAG repeats in the HTT gene. His 25-year-old sister is considering predictive testing. What is the most important consideration?\n\nA) She has a 25% chance of inheriting the expansion\nB) Insurance discrimination is not a concern with GINA protection\nC) Psychological counseling should be provided before and after testing\nD) Testing should be delayed until she develops symptoms\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: C**\n*Explanation:* Pre-symptomatic testing for Huntington disease requires extensive genetic counseling and psychological support. While GINA provides some protection, it doesn't cover life or disability insurance. The sister has a 50% risk (not 25%). Testing asymptomatic individuals requires careful consideration of psychological readiness.\n</details>\n\n### Question 2\nA couple's first child has spinal muscular atrophy type I with 2 copies of SMN2. Both parents are confirmed carriers. What is the recurrence risk and likely prognosis for future affected children?\n\nA) 25% risk; variable severity depending on SMN2 copies\nB) 50% risk; all affected will have type I SMA\nC) 25% risk; severity correlates with SMN1 deletion size\nD) <1% risk due to de novo mutations\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A**\n*Explanation:* SMA is autosomal recessive with 25% recurrence risk. Severity correlates with SMN2 copy number (not SMN1 deletion size). While this child has type I, future affected children could have different SMN2 copy numbers and thus different severity.\n</details>\n\n### Question 3\nA 2-year-old girl presents with loss of purposeful hand movements and repetitive hand-wringing after normal early development. Which test is most appropriate?\n\nA) Chromosomal microarray\nB) MECP2 sequencing\nC) Metabolic screening\nD) SMN1 deletion analysis\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n*Explanation:* This presentation is classic for Rett syndrome. Regression after normal development with stereotypic hand movements strongly suggests MECP2 mutation. While CMA might be considered for ID evaluation, the specific phenotype directs testing.\n</details>\n\n### Question 4\nA woman with a family history of Fragile X syndrome is found to have 75 CGG repeats. What is her approximate risk of expansion to full mutation in offspring?\n\nA) 3.7%\nB) 31.1%\nC) 80.1%\nD) 100%\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n*Explanation:* Risk of expansion correlates with premutation size. For 70-79 repeats, the risk is approximately 31.1%. This risk increases with larger premutations, reaching near 100% for repeats >100.\n</details>\n\n### Question 5\nA newborn boy has severe hypotonia, respiratory distress, and club feet. His mother has mild grip myotonia. What is the most likely diagnosis?\n\nA) Congenital myotonic dystrophy\nB) Spinal muscular atrophy type 0\nC) Prader-Willi syndrome\nD) Duchenne muscular dystrophy\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A**\n*Explanation:* Congenital DM1 presents with severe hypotonia, respiratory issues, and club feet. Maternal transmission is almost universal for congenital form. Mother's mild myotonia suggests she has DM1 with smaller expansion.\n</details>\n\n### Question 6\nA couple's first pregnancy was affected with anencephaly. What folic acid supplementation is recommended for the next pregnancy?\n\nA) 400 Œºg daily starting at conception\nB) 400 Œºg daily starting 3 months pre-conception\nC) 4 mg daily starting at conception\nD) 4 mg daily starting 3 months pre-conception\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: D**\n*Explanation:* After a previous NTD, high-dose folic acid (4 mg) is recommended starting 3 months before conception and continuing through the first trimester. This reduces recurrence risk from 2-3% to approximately 1%.\n</details>\n\n### Question 7\nA 10-year-old boy with intellectual disability and autism has a head circumference >97th percentile. Which genetic test should be prioritized?\n\nA) Fragile X testing\nB) PTEN sequencing\nC) Chromosomal microarray\nD) MECP2 duplication testing\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n*Explanation:* Macrocephaly with ASD/ID strongly suggests PTEN mutation. While CMA is reasonable first-tier testing, the specific finding of macrocephaly directs testing toward PTEN-related disorders.\n</details>\n\n### Question 8\nA male infant has pulmonary valve stenosis, short stature, and cryptorchidism. His mother has similar facial features and short stature. What is the most likely diagnosis?\n\nA) Turner syndrome\nB) Noonan syndrome\nC) DiGeorge syndrome\nD) Williams syndrome\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B**\n*Explanation:* Noonan syndrome features include pulmonary valve stenosis, short stature, cryptorchidism, and distinctive facial features. Autosomal dominant inheritance explains affected mother. Turner syndrome only affects females.\n</details>\n\n### Question 9\nIn Duchenne muscular dystrophy, which finding indicates carrier status in the mother?\n\nA) Elevated CK levels\nB) Calf pseudohypertrophy\nC) Molecular confirmation of heterozygous mutation\nD) Positive Gower sign\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: C**\n*Explanation:* Molecular testing is required for reliable carrier detection in DMD. CK levels are unreliable in carriers. Clinical findings are rare in carriers due to favorable X-inactivation.\n</details>\n\n### Question 10\nA 4-year-old boy has progressive proximal muscle weakness with preserved reflexes and normal intelligence. CK is 12,000. What is the best initial test?\n\nA) DMD deletion/duplication analysis\nB) SMN1 deletion analysis\nC) Muscle biopsy\nD) Nerve conduction studies\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A**\n*Explanation:* Very high CK with proximal weakness suggests muscular dystrophy. DMD deletion/duplication analysis detects 80% of mutations. This should be performed before invasive muscle biopsy. Normal reflexes argue against SMA.\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Completion Checklist](#-topic-4-completion-checklist)**\n\n---\n\n## ‚úÖ Topic 4 Completion Checklist\n\n### ‚úÖ Core Knowledge Areas\n- [ ] Trinucleotide repeat thresholds memorized\n- [ ] Anticipation patterns understood\n- [ ] X-linked inheritance risks calculated\n- [ ] DMD/BMD reading frame rule applied\n- [ ] SMA types and SMN2 correlation clear\n- [ ] Fragile X premutation risks known\n- [ ] Neural tube defect prevention understood\n- [ ] CHARGE diagnostic criteria memorized\n- [ ] Noonan syndrome features recognized\n- [ ] Testing algorithms practiced\n\n### üéØ Clinical Skills\n- [ ] Can differentiate central vs peripheral hypotonia\n- [ ] Know when to order CMA vs targeted testing\n- [ ] Understand carrier screening recommendations\n- [ ] Can counsel about prenatal testing options\n- [ ] Recognize red flags for regression\n- [ ] Apply testing to specific phenotypes\n\n### üìö Test Preparation\n- [ ] Completed all practice questions\n- [ ] Reviewed incorrect answers\n- [ ] Created personal mnemonics\n- [ ] Practiced risk calculations\n- [ ] Reviewed testing methodologies\n- [ ] Made flashcards for repeat thresholds\n\n### üîÑ Final Review\n- [ ] Cross-referenced with practice guidelines\n- [ ] Checked detection rates for carrier screening\n- [ ] Verified inheritance patterns\n- [ ] Confirmed high-yield facts memorized\n\n---\n\n## üéì Key Takeaway Messages\n\n1. **Trinucleotide repeats** show predictable patterns: paternal for HD, maternal for DM1/FXS\n2. **Reading frame** predicts severity in dystrophinopathies\n3. **SMN2 copy number** modifies SMA phenotype\n4. **Premutation carriers** have distinct risks (POI, FXTAS)\n5. **Carrier screening** detection rates vary by ethnicity\n6. **Regression** requires different evaluation than static DD\n7. **Macrocephaly + ASD** ‚Üí think PTEN\n8. **High-dose folate** prevents NTD recurrence\n9. **RASopathies** share overlapping features\n10. **X-linked** carrier risks require molecular confirmation\n\n---\n\n## üîó Navigation\n\n**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Organ Systems](topic3-organ-systems-a.md)** | **[‚û°Ô∏è Next Topic: Metabolic Disorders](topic5-metabolic-disorders.md)**\n\n---\n\n**üïí Study Time Recommendation:** 12-15 hours  \n**üóìÔ∏è Review Schedule:** Review this topic after completing Topic 6\n\n**üèÜ Completion Status:** Topic 4 of 6 complete\n\n---\n\n**Remember:** This guide covers testable material for the genetic counseling board exam. Focus on recognition patterns, inheritance risks, and testing strategies rather than detailed molecular mechanisms.\n\nGood luck with your studies\\! üß¨\nEOF < /dev/null"
}